[go: up one dir, main page]

NO20033839L - Transplantatrejeksjonssuppressorer - Google Patents

Transplantatrejeksjonssuppressorer

Info

Publication number
NO20033839L
NO20033839L NO20033839A NO20033839A NO20033839L NO 20033839 L NO20033839 L NO 20033839L NO 20033839 A NO20033839 A NO 20033839A NO 20033839 A NO20033839 A NO 20033839A NO 20033839 L NO20033839 L NO 20033839L
Authority
NO
Norway
Prior art keywords
graft rejection
ailim
transplantatrejeksjonssuppressorer
allotransplantation
xenotransplantation
Prior art date
Application number
NO20033839A
Other languages
English (en)
Other versions
NO331690B1 (no
NO20033839D0 (no
Inventor
Seiichi Suzuki
Mitsuaki Isobe
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO20033839D0 publication Critical patent/NO20033839D0/no
Publication of NO20033839L publication Critical patent/NO20033839L/no
Publication of NO331690B1 publication Critical patent/NO331690B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Graft Or Block Polymers (AREA)
  • External Artificial Organs (AREA)
  • Transplanting Machines (AREA)
  • Soil Working Implements (AREA)
  • Cylinder Crankcases Of Internal Combustion Engines (AREA)
NO20033839A 2001-03-01 2003-08-29 Forbindelse, og farmasoytisk kombinasjon av forbindelse, som har en aktivitet til a modulere signaloverforing formidlet av AILIM for forsterkning av virkningen av immunsupprimerende midler pa undertrykkelse, behandling eller forebyggelse av transplantatavstotning ved transplantasjon av et organ, del av et organ eller et vev. NO331690B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001056209 2001-03-01
JP2001056216 2001-03-01
JP2002008028 2002-01-16
PCT/JP2002/000930 WO2002070010A1 (fr) 2001-03-01 2002-02-05 Inhibiteurs de rejet du greffon

Publications (3)

Publication Number Publication Date
NO20033839D0 NO20033839D0 (no) 2003-08-29
NO20033839L true NO20033839L (no) 2003-11-03
NO331690B1 NO331690B1 (no) 2012-02-27

Family

ID=27346134

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20033839A NO331690B1 (no) 2001-03-01 2003-08-29 Forbindelse, og farmasoytisk kombinasjon av forbindelse, som har en aktivitet til a modulere signaloverforing formidlet av AILIM for forsterkning av virkningen av immunsupprimerende midler pa undertrykkelse, behandling eller forebyggelse av transplantatavstotning ved transplantasjon av et organ, del av et organ eller et vev.
NO20110218A NO20110218L (no) 2001-03-01 2011-02-08 Transplantatrejeksjonssuppressorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20110218A NO20110218L (no) 2001-03-01 2011-02-08 Transplantatrejeksjonssuppressorer

Country Status (24)

Country Link
US (2) US7438905B2 (no)
EP (2) EP1374901B9 (no)
JP (1) JP4212278B2 (no)
KR (1) KR100609444B1 (no)
CN (1) CN1518458B (no)
AT (2) ATE352318T1 (no)
AU (1) AU2002228435B2 (no)
BR (1) BR0207787A (no)
CA (1) CA2439858C (no)
CY (1) CY1110143T1 (no)
CZ (1) CZ20032406A3 (no)
DE (2) DE60217839T2 (no)
DK (1) DK1769807T3 (no)
ES (1) ES2344219T3 (no)
HU (2) HU228045B1 (no)
IL (2) IL156845A0 (no)
MX (1) MXPA03006736A (no)
NO (2) NO331690B1 (no)
NZ (1) NZ527076A (no)
PT (1) PT1769807E (no)
RU (1) RU2263512C2 (no)
SI (1) SI1769807T1 (no)
SK (1) SK288048B6 (no)
WO (1) WO2002070010A1 (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
HRP20050176A2 (en) * 1999-12-16 2005-08-31 Teva Pharmaceutical Industries Ltd. Novel processes for making - and a new crystalline form of-leflunomide
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
RU2291675C2 (ru) * 2004-07-09 2007-01-20 Институт теоретической и экспериментальной биофизики РАН Способ обработки трансплантатов для сердечно-сосудистой хирургии
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
JP2006321765A (ja) * 2005-05-20 2006-11-30 Mikiko Ueda 肝移植における拒絶反応の予防又は治療薬、或いは拒絶反応とは断定できない肝機能異常の治療薬
AU2008247382B2 (en) * 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
WO2011007747A1 (ja) 2009-07-16 2011-01-20 大塚化学株式会社 糖鎖付加ａｉｌｉｍ細胞外ドメイン及びその製造方法
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
EP2558024B1 (en) * 2010-04-12 2017-03-08 The University Of Miami Macroporous bioengineered scaffolds for cell transplantation
KR101905113B1 (ko) * 2011-03-31 2018-10-10 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Icos에 대한 항체 및 이의 용도
US20150139994A1 (en) * 2013-11-12 2015-05-21 The Regents Of The University Of California Compositions and methods for preventing allogeneic immune rejection
CN105744949A (zh) * 2013-11-22 2016-07-06 夏尔维洛药品公司 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2942384C (en) 2014-03-12 2024-01-23 Icahn School Of Medicine At Mount Sinai Method for identifying kidney allograft recipients at risk for chronic injury
ES2850281T3 (es) 2014-06-26 2021-08-26 Icahn School Med Mount Sinai Método para diagnosticar el rechazo agudo subclínico y clínico mediante el análisis de conjuntos de genes predictivos, un agente terapéutico para usar en el tratamiento y kits para determinar la expresión
CA2953368C (en) * 2014-06-26 2022-11-08 Icahn School Of Medicine At Mount Sinai Methods for diagnosing risk of renal allograft fibrosis and rejection
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
HK1250032A1 (zh) 2015-12-03 2018-11-23 Glaxosmithkline Intellectual Property Development Limited 作为sting调节剂的环状嘌呤二核苷酸
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
CN109563081A (zh) 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
MX387354B (es) 2016-04-07 2025-03-18 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas útiles como moduladores de proteínas.
PE20190106A1 (es) 2016-05-05 2019-01-15 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homologo zeste 2
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018015879A1 (en) 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US20200062735A1 (en) 2017-02-27 2020-02-27 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN110869049A (zh) 2017-06-09 2020-03-06 葛兰素史克知识产权开发有限公司 组合疗法
CA3066038A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2018225035A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
JP2020533380A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
RU2688172C1 (ru) * 2018-04-05 2019-05-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ профилактики отторжения трансплантата трупной почки
ES3037279T3 (en) 2018-04-16 2025-09-30 Icahn School Med Mount Sinai Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3801615A1 (en) 2018-05-31 2021-04-14 GlaxoSmithKline Intellectual Property Development Ltd Combined therapy with icos binding proteins and argininemethyltransferase inhibitors
US20210267973A1 (en) 2018-05-31 2021-09-02 Glaxosmithkline Intellectual Property Development Limited Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2020086479A1 (en) 2018-10-22 2020-04-30 Glaxosmithkline Intellectual Property Development Limited Dosing
US20200368369A1 (en) * 2019-05-22 2020-11-26 Wyvern Pharmaceuticals Inc. Composition for endogenous production of checkpoint protein precursors
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046293A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab
PH12022550671A1 (en) 2019-09-27 2023-05-29 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
CA3164751A1 (en) 2019-12-18 2021-06-24 Benjamin Joseph MORROW Compounds
CN113294813B (zh) * 2020-02-24 2022-09-02 宁波方太厨具有限公司 一种电磁灶
CN115397861A (zh) 2020-04-14 2022-11-25 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CA3171557A1 (en) 2020-04-14 2021-10-21 Marc S. BALLAS Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
WO2021209358A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
JP2024509529A (ja) 2021-03-02 2024-03-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｄｎｍｔ１阻害剤としての置換ピリジン
WO2022208353A1 (en) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
CA3219336A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
CN1188528C (zh) * 1991-06-11 2005-02-09 血液研究中心 细胞间粘附分子－3及其配体
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3162438B2 (ja) 1991-09-12 2001-04-25 住友製薬株式会社 高感度特異的抗体測定法
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5747461A (en) * 1994-07-26 1998-05-05 Markov; Angel K. Synergistic administration of cyclosporine and fructose diphosphate
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
IL129024A0 (en) 1996-09-18 2000-02-17 Zetesis Spa Use of proteins as agent against autoimmune diseases
JP4048294B2 (ja) * 1996-11-08 2008-02-20 バイオジェン・アイデック・インコーポレイテッド ある種の抗体とヒトｂ７．１およびｂ７．２コスティミュラトリー抗原との間の独特の結合相互作用の同定
WO1998037415A1 (en) 1997-02-20 1998-08-27 The Regents Of The University Of California ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME
FI107538B (fi) * 1997-02-26 2001-08-31 Raisio Benecol Oy Menetelmä stanoliesterien valmistamiseksi
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
CA2305350C (en) * 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JPH11228442A (ja) * 1998-02-09 1999-08-24 Cypros Pharmaceut Corp 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
JP2000154151A (ja) * 1998-09-14 2000-06-06 Kyo Jo 免疫抑制剤
AU767241B2 (en) * 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
WO2000019988A1 (en) 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
NZ583002A (en) * 1999-02-03 2011-12-22 Amgen Inc Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation
BR0010711A (pt) 1999-05-06 2002-02-13 Genetics Inst Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
AU6615500A (en) 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
WO2001012658A2 (en) 1999-08-11 2001-02-22 Isis Innovations Limited Human icos ligand and application thereof
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP2003508088A (ja) 1999-09-03 2003-03-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５２個のヒト分泌タンパク質
JP4737905B2 (ja) 1999-09-21 2011-08-03 ジェネティクス インスティテュート，エルエルシー Ｇｌ５０分子およびその使用
EP1224201A4 (en) 1999-10-29 2005-03-02 Human Genome Sciences Inc 32 HUMAN SECRETED PROTEINS
WO2001064704A1 (en) 2000-03-02 2001-09-07 Mayo Foundation For Medical Education And Research hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
AU1796902A (en) 2000-11-28 2002-06-11 Amgen Inc Novel polypeptides involved in immune response
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤

Also Published As

Publication number Publication date
DK1769807T3 (da) 2010-07-19
WO2002070010A1 (fr) 2002-09-12
HUP0303332A2 (hu) 2003-12-29
EP1374901A4 (en) 2004-09-15
RU2003129166A (ru) 2005-03-10
EP1374901B9 (en) 2007-11-07
DE60217839D1 (de) 2007-03-15
CN1518458B (zh) 2010-05-26
CN1518458A (zh) 2004-08-04
HK1102293A1 (en) 2007-11-16
CA2439858A1 (en) 2002-09-12
PT1769807E (pt) 2010-06-02
DE60217839T2 (de) 2007-11-15
EP1769807A1 (en) 2007-04-04
EP1769807B1 (en) 2010-04-07
ES2344219T3 (es) 2010-08-20
IL156845A (en) 2011-10-31
ATE463256T1 (de) 2010-04-15
BR0207787A (pt) 2004-03-23
MXPA03006736A (es) 2004-05-31
AU2002228435B2 (en) 2005-03-10
EP1374901B1 (en) 2007-01-24
KR100609444B1 (ko) 2006-08-03
US20040253229A1 (en) 2004-12-16
SK12142003A3 (sk) 2004-05-04
JP4212278B2 (ja) 2009-01-21
US20090047292A1 (en) 2009-02-19
DE60235928D1 (de) 2010-05-20
HK1061531A1 (en) 2004-09-24
HU228108B1 (en) 2012-11-28
RU2263512C2 (ru) 2005-11-10
ATE352318T1 (de) 2007-02-15
SK288048B6 (sk) 2013-03-01
CA2439858C (en) 2009-07-14
CY1110143T1 (el) 2015-01-14
EP1374901A1 (en) 2004-01-02
NO331690B1 (no) 2012-02-27
SI1769807T1 (sl) 2010-08-31
NZ527076A (en) 2006-03-31
CZ20032406A3 (cs) 2004-10-13
US7438905B2 (en) 2008-10-21
HU228045B1 (en) 2012-09-28
NO20110218L (no) 2003-11-03
IL156845A0 (en) 2004-02-08
NO20033839D0 (no) 2003-08-29
KR20030078946A (ko) 2003-10-08
JP2003277293A (ja) 2003-10-02

Similar Documents

Publication Publication Date Title
NO20033839L (no) Transplantatrejeksjonssuppressorer
ATE510562T1 (de) Anti-ailim antikörper zur behandlung von crohn's
DK1487431T3 (da) Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl
ATE232730T1 (de) Verfahren und zusammensetzungen zur verhinderung der antikörper-vermittelten abstossung von xenogenen transplantaten
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
NO941462L (no) Metoder og sammensetninger for profylaktisk og/eller terapeutisk behandling av organhypofunksjon
MY137250A (en) Method of treatment of transplant rejection
UA85996C2 (ru) Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору
ES2097208T3 (es) Composiciones y procedimientos terapeuticos y sinergicos.
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
WO2004039248A3 (en) Repairing or replacing tissues or organs
PL350408A1 (en) Antithrombotic use of glycine betaine
DK1112083T3 (da) Behandling af mikrovaskulære angiopatier
ATE417921T1 (de) Herstellung von tacrolimus (fk-506) unter verwendung neuer streptomyces-spezies
ATE489963T1 (de) Chaperonin-10-immunosuppression
WO2004052305A3 (en) Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
IL178094A (en) Enantiomers, their use in the treatment or prevention of viral diseases, allergic immune diseases, autoimmune diseases or graft rejection, and methods of preparation of these substances
BR112021010615A2 (pt) Clazakizumab no tratamento de rejeição crônica de transplante de órgãos mediada por anticorpos
Olausson et al. Liver transplantation using cavoportal hemitransposition-a life-saving procedure in the presence of extensive portal vein thrombosis
DK1222854T3 (da) Forebyggelse og behandling af sygdomme forbundet med blodkoagulering
DE60213766D1 (de) Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
WO2006077592A3 (en) Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
Ikegami et al. Splenectomy as flow modulation strategy and risk factors of de novo portal vein thrombosis in adult‐to‐adult living donor liver transplantation
BR0012072A (pt) Processo para o tratamento ou prevenção de vasoespasmo de enxerto coronário
Knight et al. Dual renal transplant from a non-heart beating donor

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees